We have located links that may give you full text access.
Differential effects of metformin on immune-mediated and androgen-mediated non-cancer skin diseases in diabetes patients: a retrospective cohort study.
BACKGROUND: Metformin's effects on non-cancer skin diseases are rarely investigated.
OBJECTIVE: To investigate immune-mediated (urticaria, allergic contact dermatitis and psoriasis) and androgen-mediated (acanthosis nigricans, hidradenitis suppurativa and acne) skin diseases associated with metformin use.
METHODS: Metformin initiators (n=234,585) and non-metformin initiators (n=125,921) within the initial 12 months of antidiabetic drugs prescription during 1999-2009 were followed up until December 31, 2011. Cox regression weighted for propensity score was used to estimate hazard ratios for metformin initiators versus non-metformin initiators in intention-to-treat (ITT) and per-protocol (PP) analyses.
RESULTS: For immune-mediated skin diseases, hazard ratios were 0.930 (95% confidence interval: 0.920-0.940) and 0.930 (0.918-0.943) in ITT and PP analyses, respectively; and the hazard ratios for each specific outcome were all significantly below unity. For androgen-mediated skin diseases, the ITT and PP hazard ratios were 1.110 (1.060-1.162) and 0.990 (0.935-1.048), respectively; and all hazard ratios were not significant for each specific outcome except for acne in the ITT analysis (hazard ratio: 1.116, 95% confidence interval: 1.064-1.170).
CONCLUSION: Metformin use is associated with a significantly lower risk of immune-mediated skin diseases but a lack of preventive effect on androgen-mediated skin diseases.
OBJECTIVE: To investigate immune-mediated (urticaria, allergic contact dermatitis and psoriasis) and androgen-mediated (acanthosis nigricans, hidradenitis suppurativa and acne) skin diseases associated with metformin use.
METHODS: Metformin initiators (n=234,585) and non-metformin initiators (n=125,921) within the initial 12 months of antidiabetic drugs prescription during 1999-2009 were followed up until December 31, 2011. Cox regression weighted for propensity score was used to estimate hazard ratios for metformin initiators versus non-metformin initiators in intention-to-treat (ITT) and per-protocol (PP) analyses.
RESULTS: For immune-mediated skin diseases, hazard ratios were 0.930 (95% confidence interval: 0.920-0.940) and 0.930 (0.918-0.943) in ITT and PP analyses, respectively; and the hazard ratios for each specific outcome were all significantly below unity. For androgen-mediated skin diseases, the ITT and PP hazard ratios were 1.110 (1.060-1.162) and 0.990 (0.935-1.048), respectively; and all hazard ratios were not significant for each specific outcome except for acne in the ITT analysis (hazard ratio: 1.116, 95% confidence interval: 1.064-1.170).
CONCLUSION: Metformin use is associated with a significantly lower risk of immune-mediated skin diseases but a lack of preventive effect on androgen-mediated skin diseases.
Full text links
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app